Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has received an average recommendation of “Buy” from the eighteen ratings firms that are presently covering the company. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, fourteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $96.04.

RARE has been the subject of a number of analyst reports. Jefferies Group set a $109.00 price target on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Sunday, September 18th. Piper Jaffray Cos. set a $82.00 price target on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, August 9th. Credit Suisse Group AG reiterated a “buy” rating and issued a $101.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 9th. Zacks Investment Research downgraded shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, November 11th. Finally, Cowen and Company reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 9th.

In related news, CFO Shalini Sharp sold 24,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $71.20, for a total transaction of $1,708,800.00. Following the sale, the chief financial officer now directly owns 69,387 shares in the company, valued at approximately $4,940,354.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, October 14th. The shares were sold at an average price of $63.02, for a total transaction of $1,260,400.00. Following the sale, the chief executive officer now owns 480,632 shares in the company, valued at $30,289,428.64. The disclosure for this sale can be found here. Corporate insiders own 10.10% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its stake in shares of Ultragenyx Pharmaceutical by 14.8% in the third quarter. Price T Rowe Associates Inc. MD now owns 1,827,607 shares of the biopharmaceutical company’s stock worth $129,650,000 after buying an additional 235,630 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its stake in Ultragenyx Pharmaceutical by 85.4% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 8,217 shares of the biopharmaceutical company’s stock valued at $582,000 after buying an additional 3,786 shares in the last quarter. Baker BROS. Advisors LP purchased a new stake in Ultragenyx Pharmaceutical during the third quarter valued at about $7,094,000. Capital International Sarl purchased a new stake in Ultragenyx Pharmaceutical during the third quarter valued at about $6,048,000. Finally, Capital International Investors purchased a new stake in Ultragenyx Pharmaceutical during the third quarter valued at about $34,072,000. Institutional investors own 90.87% of the company’s stock.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down 3.27% during mid-day trading on Tuesday, hitting $81.89. The company’s stock had a trading volume of 278,286 shares. The company has a 50-day moving average price of $68.13 and a 200-day moving average price of $64.30. Ultragenyx Pharmaceutical has a 1-year low of $46.52 and a 1-year high of $117.12. The stock’s market cap is $3.35 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($1.64) EPS for the quarter, missing analysts’ consensus estimates of ($1.53) by $0.11. During the same period last year, the company posted ($1.03) earnings per share. Analysts predict that Ultragenyx Pharmaceutical will post ($6.15) EPS for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.